Lukotas LC Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, formulated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors (CysLT1), mitigating airway inflammation and bronchoconstriction commonly associated with asthma and allergic rhinitis. The synergistic action of these agents provides comprehensive relief from allergic symptoms by targeting multiple inflammatory pathways. Lukotas LC is indicated for patients requiring both antihistaminic and anti-leukotriene therapy, improving symptom control and enhancing quality of life. It is generally well tolerated, with adverse effects including headache, fatigue, and gastrointestinal disturbances being infrequent and mild. Caution is advised in patients with hepatic impairment or a history of neuropsychiatric events. The medication should be taken as prescribed, typically once daily in the evening, with or without food. Lukotas LC Tablet offers an effective therapeutic option for individuals with persistent allergic conditions unresponsive to monotherapy.